Genetically proxied glucagon-like peptide-1 receptor perturbation and risk of mood disorders: a Mendelian randomization study.

ABSTRACT:

Background

Glucagon-like peptide-1 receptor (GLP1R) agonists have gained attention for their role in diabetes treatment along with their diverse effects, such as appetite suppression, suggesting potential psychiatric benefits. This study aimed to assess the effect of GLP1R perturbation on mood disorders based on protein and biomarker levels using Mendelian randomization (MR) approach.

Methods

We conducted two-sample MR using summary statistics for GLP1R plasma levels (n = 3,301) from the INTERVAL study, glycated hemoglobin (HbA1c) levels (n = 128,610) from the Meta-Analyses of Glucose and Insulin-related traits Consortium, and bipolar disorder (BD: 371 cases/360,823 controls) and major depressive disorder (MDD: 776 cases/360,418 controls) incidences from the UK Biobank. Gene

SUBMITTER: Jeon Y 

PROVIDER: S-EPMC12330103 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature